Do beractant dosing intervals make a difference?

Autor:	Kathleen E. Lieberman, Susan M. Hieber, Steven M. Donn, Mohammad A. Attar
Rok vydání:	2010
Předmět:	Mechanical ventilation Respiratory distress business.industry medicine.medical_treatment Birth weight Gestational age Anesthesia Pediatrics Perinatology and Child Health medicine Gestation Dosing Respiratory system business Beractant medicine.drug
Zdroj:	Journal of Neonatal-Perinatal Medicine. 3:21-25
ISSN:	1934-5798
DOI:	10.3233/npm-2010-0088
Popis:	Introduction: Surfactant dosing in extremely premature infants is not based on rigorous human pharmacokinetic data. Beractant (Survanta ) is an animal-derived surfactant. The manufacturer's package insert suggests a dosing interval of "no sooner than 6 hours" after a preceding dose. Other animal-derived surfactant preparations are commonly dosed at 12 hour intervals. We evaluated Survanta use following a change in the re-treatment dosing interval from no less than 6 (Q6 h) to no less than 12 hours (Q12 h) in June 2007. Method: We used a retrospective comparison of two cohorts, Q6 h and Q12 h, born at
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0fbfe2d02a1178a257d2ed633c9ca487 https://doi.org/10.3233/npm-2010-0088 Zobrazit plný text záznamu